Several studies have demonstrated the alleviative and therapeutic effects of GCs on COVID-19 due to their role in inhibiting dysfunctional systemic inflammation (Hu et al., 2020), reducing inflammatory-coagulant-fibroproliferative effects (Villar et al., 2020), and rapidly decreasing C-reactive protein and interleukin-6 (IL-6) levels (Li et al., 2021). The gene discussed is IL6; the disease is COVID-19.